Holen Sie sich die Stockscreener-App
333.00
3.38%
10.89
Vorhandelsmarkt:
325.08
-7.92
-2.38%
Schlusskurs vom Vortag:
$322.11
Offen:
$320.66
24-Stunden-Volumen:
967.59K
Relative Volume:
0.72
Marktkapitalisierung:
$44.43B
Einnahmen:
$3.71B
Nettoeinkommen (Verlust:
$313.75M
KGV:
147.53
EPS:
2.2571
Netto-Cashflow:
$465.38M
1W Leistung:
+0.81%
1M Leistung:
+6.25%
6M Leistung:
-28.38%
1J Leistung:
+40.05%
1-Tages-Spanne:
$319.00
$333.56
1-Wochen-Bereich:
$313.54
$333.56
52-Wochen-Spanne:
$225.84
$495.55
Alnylam Pharmaceuticals Inc Stock (ALNY) Company Profile
Firmenname
Alnylam Pharmaceuticals Inc
Sektor
Branche
Telefon
(617) 551-8200
Adresse
675 WEST KENDALL STREET, CAMBRIDGE, MA
Compare ALNY vs VRTX, REGN, ARGX, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ALNY
Alnylam Pharmaceuticals Inc
|
333.00 | 42.98B | 3.71B | 313.75M | 465.38M | 2.2571 |
VRTX
Vertex Pharmaceuticals Inc
|
440.05 | 110.97B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
746.46 | 79.17B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
809.27 | 49.73B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
305.64 | 34.37B | 5.36B | 287.73M | 924.18M | 2.5229 |
Alnylam Pharmaceuticals Inc Stock (ALNY) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-16 | Herabstufung | Jefferies | Buy → Hold |
| 2026-01-28 | Fortgesetzt | Barclays | Overweight |
| 2026-01-07 | Fortgesetzt | Oppenheimer | Outperform |
| 2025-08-04 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2025-08-04 | Hochstufung | Wolfe Research | Underperform → Peer Perform |
| 2025-07-30 | Fortgesetzt | Raymond James | Outperform |
| 2025-07-21 | Eingeleitet | Truist | Buy |
| 2025-03-31 | Eingeleitet | Redburn Atlantic | Buy |
| 2025-03-24 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2024-11-12 | Herabstufung | Wolfe Research | Peer Perform → Underperform |
| 2024-10-16 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-08-16 | Hochstufung | Goldman | Neutral → Buy |
| 2024-02-16 | Herabstufung | Goldman | Buy → Neutral |
| 2024-02-15 | Eingeleitet | Wolfe Research | Peer Perform |
| 2023-12-08 | Eingeleitet | Wells Fargo | Equal Weight |
| 2023-10-11 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2023-09-29 | Eingeleitet | Raymond James | Outperform |
| 2023-05-05 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2023-04-26 | Eingeleitet | SMBC Nikko | Neutral |
| 2023-03-21 | Eingeleitet | Bernstein | Outperform |
| 2023-01-18 | Eingeleitet | Canaccord Genuity | Buy |
| 2022-09-09 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2022-07-13 | Eingeleitet | Cantor Fitzgerald | Neutral |
| 2022-06-27 | Herabstufung | Guggenheim | Buy → Neutral |
| 2022-06-07 | Eingeleitet | William Blair | Outperform |
| 2022-04-25 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2022-03-01 | Eingeleitet | Citigroup | Buy |
| 2022-02-03 | Hochstufung | Guggenheim | Neutral → Buy |
| 2022-01-03 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2021-11-22 | Hochstufung | Goldman | Neutral → Buy |
| 2021-11-22 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2021-11-01 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2021-10-04 | Hochstufung | UBS | Neutral → Buy |
| 2021-08-04 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2021-02-22 | Herabstufung | Guggenheim | Buy → Neutral |
| 2021-02-12 | Herabstufung | Citigroup | Buy → Neutral |
| 2021-02-12 | Bestätigt | H.C. Wainwright | Buy |
| 2021-01-25 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2020-09-30 | Fortgesetzt | Berenberg | Hold |
| 2020-09-08 | Eingeleitet | Citigroup | Buy |
| 2020-08-11 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2020-05-13 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2020-05-07 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-04-24 | Fortgesetzt | Evercore ISI | Outperform |
| 2020-03-19 | Eingeleitet | Berenberg | Buy |
| 2019-12-19 | Bestätigt | Chardan Capital Markets | Buy |
| 2019-11-20 | Eingeleitet | Oppenheimer | Outperform |
| 2019-11-13 | Eingeleitet | BofA/Merrill | Buy |
| 2019-05-23 | Fortgesetzt | Goldman | Neutral |
| 2019-04-12 | Eingeleitet | Evercore ISI | Outperform |
| 2019-03-06 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2019-03-05 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2019-01-23 | Eingeleitet | UBS | Neutral |
| 2018-10-01 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2018-08-13 | Bestätigt | Stifel | Buy |
| 2018-08-07 | Hochstufung | Stifel | Hold → Buy |
| 2018-05-04 | Bestätigt | Stifel | Hold |
| 2018-03-28 | Eingeleitet | Evercore ISI | In-line |
Alle ansehen
Alnylam Pharmaceuticals Inc Aktie (ALNY) Neueste Nachrichten
Whats the beta of Alnylam Pharmaceuticals Inc stockWeekly Gains Report & Short-Term Swing Trade Alerts - baoquankhu1.vn
Oligonucleotides Market Research and Competitive Landscape Report 2026 Featuring Novartis, Astellas, Alnylam Pharmaceuticals, Ionis Pharmaceuticals - Yahoo Finance
Alnylam Pharmaceuticals (ALNY) presents Vutrisiran ATTR-CM data at ACC.26 - MSN
Alnylam to Webcast Presentation at 2013 UBS Global Healthcare Conference - Yahoo
Is Alnylam Pharmaceuticals (ALNY) The Best Growth Stock? - Insider Monkey
A Look At Alnylam Pharmaceuticals’ (ALNY) Valuation After Recent Mixed Share Price Performance - simplywall.st
10 Best Growth Stocks to Buy With Highest Upside Potential - Insider Monkey
Alnylam Achieves Leading Trading Position Despite Declining Volume as Revenue Surges - Bitget
ALNY (Alnylam Pharmaceuticals) Earnings Yield (Joel Greenblatt) % : 1.13% (As of Dec. 2025) - GuruFocus
ALNY Stock Price, Quote & Chart | ALNYLAM PHARMACEUTICALS INC (NASDAQ:ALNY) - ChartMill
Alnylam Pharmaceuticals (ALNY) Achieved Free Cash Flow Breakeven in 2025 - Yahoo Finance
RBC Capital Maintains Alnylam Pharmaceuticals(ALNY.US) With Buy Rating, Maintains Target Price $450 - Moomoo
Alnylam Cardiovascular Data Highlights Potential Upside In ATTR-CM And Hypertension - Yahoo Finance
Antisense Oligonucleotides Market 2026-2033 | US$ 5,286.96 - openPR.com
Trading Systems Reacting to (ALNY) Volatility - Stock Traders Daily
Mach Natural Resources, Mesoblast And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session - Sahm
Is the options market predicting a spike in Alnylam Pharmaceuticals stock? - msn.com
Alnylam (ALNY) CHRO McLaughlin sells shares worth $1.27 million By Investing.com - Investing.com India
Alnylam (ALNY) CHRO McLaughlin sells shares worth $1.27 million - Investing.com
Alnylam (NASDAQ: ALNY) HR chief auto-sells shares to cover RSU taxes - Stock Titan
Alnylam (NASDAQ: ALNY) HR chief details stock and option holdings - Stock Titan
Is the options market signaling a potential surge in Alnylam Pharmaceuticals shares? - Bitget
Is the Options Market Predicting a Spike in Alnylam Pharmaceuticals Stock? - Zacks Investment Research
Book value per share of Alnylam Pharmaceuticals, Inc – LSE:0HD2 - TradingView
How New Vutrisiran Outcomes and Zilebesiran Safety Data Will Impact Alnylam Pharmaceuticals (ALNY) Investors - simplywall.st
Alnylam (NASDAQ: ALNY) sets 2026 virtual meeting, board elections and pay vote - Stock Titan
[144] ALNYLAM PHARMACEUTICALS, INC. SEC Filing - Stock Titan
Alnylam Pharmaceuticals, Inc. (ALNY) Options Chain - Yahoo! Finance Canada
Alnylam Pharmaceuticals, Inc. (ALNY) stock price, news, quote and history - Yahoo Finance UK
Porphyria Treatment Market to Reach US$ 358.64 Million by 2032 - openPR.com
Alnylam announces proposed offering of $500M convertible senior notes - MSN
Perpetual Ltd Invests $2 Million in Alnylam Pharmaceuticals, Inc. $ALNY - marketbeat.com
Alnylam Pharmaceuticals, Inc. (ALNY) Stock Price, News, Quote & History - Yahoo! Finance Canada
Aberdeen Group plc Has $52.83 Million Position in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
10 Best Future Stocks to Buy for the Next 5 Years - Insider Monkey
Alnylam Pharmaceuticals (ALNY) Presents Vutrisiran ATTR-CM Data at ACC.26 - Insider Monkey
Alnylam CEO Greenstreet sells $2.23 million in stock - Investing.com
A Look At Alnylam Pharmaceuticals (ALNY) Valuation After New Cardiovascular Data And Partnerships At ACC.26 - simplywall.st
Alnylam Data Update Highlights RNAi Potential And Undervalued Share Price - Sahm
Barclays Maintains Alnylam Pharmaceuticals(ALNY.US) With Buy Rating, Maintains Target Price $527 - Moomoo
5 Biotechs That Big Pharma Could Snap Up as Oncology M&A Heats Up - 24/7 Wall St.
Alnylam Pharmaceuticals Inc (NASDAQ:ALNY) Combines Strong Growth with a Technical Breakout Setup - ChartMill
Alnylam Pharmaceuticals, Inc. $ALNY Shares Sold by Allspring Global Investments Holdings LLC - MarketBeat
Why Alnylam Pharmaceuticals Inc. (ALNY) is One of the Best High Growth Healthcare Stocks to Buy Now - insidermonkey.com
Hemophilia B Market: Rapid Increment Driven by Innovation by 2034 – DelveInsight | Pfizer, Spark Therapeutics, Sanofi, Alnylam Pharma, CSL Behring, uniQure, Novo Nordisk - Barchart
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Alnylam (ALNY) Highlights Breakthrough Vutrisiran Data at ACC An - GuruFocus
Alnylam's (ALNY) Zilebesiran Shows Promising Phase 2 Safety Data - GuruFocus
Alnylam presents cardiovascular data at ACC conference - Investing.com
Finanzdaten der Alnylam Pharmaceuticals Inc-Aktie (ALNY)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.20%
1.30%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):